Windtree Therapeutics touts Phase II data for inhaled surfactant

Windtree Therapeutics (NSDQ:WINT) reported data today from the 221-patient Phase IIb trial of its aerosolized KL4 surfactant for the treatment of respiratory distress syndrome in premature infants.

The Aerosurf trial evaluated aerosolized KL4 surfactant administered to premature infants 28 to 32 weeks gestational age in 2 dose groups with up to 2 repeat doses, compared to infants receiving nasal continuous positive airway pressure.

The trial evaluated incidence of nCPAP failure, time to nCPAP failure and physiological parameters indicating the effectiveness of lung function.

The inhaled therapy did not meet the primary endpoint of the study, which was reducing nCPAP failure at 72 hours.

Get the full story at our sister site, Drug Delivery Business News.

The post Windtree Therapeutics touts Phase II data for inhaled surfactant appeared first on MassDevice.

from MassDevice http://ift.tt/2t6zA3K